Unilink Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Unilink Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 8 Products, $3.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Unilink Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 8 Products, $3.9M Trade | TransData Nexus

Unilink Pharma Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $3.9M Total Trade · DGFT Verified

Unilink Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.9M across 8 products in 5 therapeutic categories. Based on 79 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ceftriaxone ($1.3M), Isoniazid ($600.0K), Salicylic ($550.0K).

Unilink Pharma Private Limited — Export Portfolio & Destination Treemap

Unilink Pharma Private Limited pharmaceutical export portfolio — 8 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Unilink Pharma Private Limited? — Company Overview & Market Position

Unilink Pharma Private Limited, established on February 23, 2005, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U24232TN2005PTC055459. Its authorized capital stands at ₹3.00 crore, with a paid-up capital of ₹1.60 crore. The registered office is located at New No.111, Old No.23 Parthasarathypuram, T Nagar, Chennai-600017, Tamil Nadu, India.

The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Over the years, Unilink Pharma has expanded its product portfolio to cover 80% of the therapeutic segment, employing a multi-pronged marketing approach that includes creating stock points outside India, global tendering, and offering tailor-made products to buyers with regulatory support.

What Does Unilink Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ceftriaxone$1.3M 2

Product Portfolio — Top 8 by Export Value

Unilink Pharma Private Limited exports 8 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ceftriaxone	Advanced Antibiotics	$1.3M	26	0.5%	3
2	Isoniazid	Tuberculosis Medications	$600.0K	12	0.0%	11
3	Salicylic	Combination Drugs	$550.0K	11	3.3%	4
4	Rifampicin	Advanced Antibiotics	$400.0K	8	0.0%	11
5	Miconazole	Antifungals	$300.0K	6	1.5%	6
6	Ethambutol	Tuberculosis Medications	$291.9K	6	0.0%	9
7	Pyrazinamide	Tuberculosis Medications	$291.1K	6	0.0%	8
8	Sulfadoxine	Antimalarial & Antiparasitic	$146.3K	4	0.3%	10

Unilink Pharma Private Limited exports 8 pharmaceutical products across 5 therapeutic categories with a total export value of $3.9M. The top category is Advanced Antibiotics (43.8% of portfolio), followed by Tuberculosis Medications (30.5%), indicating a concentrated portfolio with the top 5 products accounting for 81.2% of total export value.

Unilink Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Unilink Pharma operates a 30,000-square-foot manufacturing facility in Chennai, Tamil Nadu. This state-of-the-art plant is equipped to produce a wide range of pharmaceutical products, including tablets, capsules, syrups, and injections. The facility adheres to current Good Manufacturing Practices (cGMP) and holds ISO 9001 certifications, ensuring high-quality production standards.

3Key Leadership

The leadership team at Unilink Pharma comprises:

Karunakaran Vijaya: Managing Director, appointed on February 23, 2005.

Sreenivasan Karunakaran: Whole-Time Director, appointed on October 2, 2009.

These leaders bring extensive experience in pharmaceutical manufacturing and export, driving the company's growth and strategic direction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Unilink Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Unilink Pharma has made significant strides in obtaining regulatory approvals for its products in various international markets. The company's manufacturing facility is WHO-certified, indicating compliance with international standards for pharmaceutical manufacturing. Additionally, the facility holds cGMP and ISO 9001 certifications, further demonstrating its commitment to quality. While specific details regarding approvals from the US FDA, EMA, MHRA, and TGA are not publicly disclosed, the company's adherence to international standards suggests a proactive approach to meeting regulatory requirements in these regions.

2Emerging Markets

Unilink Pharma has strategically positioned itself to penetrate emerging markets in Africa, Latin America, and Southeast Asia. The company's WHO-certified manufacturing facility enhances its credibility and facilitates access to these regions. By offering a diverse product portfolio and ensuring compliance with international standards, Unilink Pharma aims to address the healthcare needs of these growing markets.

3Geographic Strategy

Unilink Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Unilink Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's adherence to international standards, including WHO certification and cGMP compliance, suggests a commitment to meeting FDA requirements for potential market entry.

2WHO & EU GMP

Unilink Pharma's manufacturing facility is WHO-certified, indicating compliance with international standards for pharmaceutical manufacturing. Additionally, the facility holds cGMP and ISO 9001 certifications, reflecting its commitment to quality. While specific details regarding EU GMP certificates and EDQM status are not publicly disclosed, the company's adherence to international standards suggests a proactive approach to meeting EU regulatory requirements.

3CDSCO & Indian Regulatory

Unilink Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian pharmaceutical regulations. The company's adherence to cGMP and ISO 9001 standards further demonstrates its commitment to quality and regulatory compliance. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available.

Unilink Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Unilink Pharma operates in a competitive landscape with several key players in the pharmaceutical manufacturing and export sector. While specific competitors are not identified in the available data, the company's focus on quality, regulatory compliance, and a diverse product portfolio positions it favorably in the market. The company's export value of $3.9 million USD across 79 shipments indicates a growing presence in the global market.

2Key Differentiators

Unilink Pharma's key differentiators include:

Quality Assurance: The company's manufacturing facility is WHO-certified and adheres to cGMP and ISO 9001 standards, ensuring high-quality products.

Diverse Product Portfolio: Unilink Pharma offers a range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories.

Global Reach: The company's export value of $3.9 million USD across 79 shipments reflects its expanding global presence.

Buyer Due Diligence Brief — Evaluating Unilink Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Unilink Pharma has demonstrated a consistent track record in pharmaceutical manufacturing and export, with a total export value of $3.9 million USD across 79 shipments. The company's adherence to international standards, including WHO certification and cGMP compliance, indicates reliability and commitment to quality. While specific details regarding export volume consistency and reliability indicators are not publicly available, the company's strategic focus on quality and regulatory compliance suggests a strong foundation for sustained performance.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

WHO Certification: Indicates compliance with international standards for pharmaceutical manufacturing.

cGMP Certification: Demonstrates adherence to current Good Manufacturing Practices.

Frequently Asked Questions — Unilink Pharma Private Limited

How many pharmaceutical products does Unilink Pharma Private Limited export from India?

Unilink Pharma Private Limited exports 8 pharmaceutical products across 5 therapeutic categories. The top exports are Ceftriaxone ($1.3M), Isoniazid ($600.0K), Salicylic ($550.0K), Rifampicin ($400.0K), Miconazole ($300.0K). Total export value is $3.9M.

What is Unilink Pharma Private Limited's total pharmaceutical export value?

Unilink Pharma Private Limited's total pharmaceutical export value is $3.9M, based on 79 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Unilink Pharma Private Limited cover?

Unilink Pharma Private Limited exports across 5 therapeutic categories. The largest are Advanced Antibiotics (43.8%, 2 products), Tuberculosis Medications (30.5%, 3 products), Combination Drugs (14.2%, 1 products).

Get Full Unilink Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.